The uncontrolled study offers support for intrathecal administration of autologous mesenchymal stem cells that secrete neurotrophic factors. Investigators call for randomized studies to better explore effects on symptoms and disease activity.
This protein shows promise as a biomarker for use in early-stage therapeutic trials, but more work is needed. An expert panel has outlined what should be done next to rapidly realize its potential.
A leading MS researcher shares three potential explanations for why the well-designed MS-SMART investigation didn’t identify any therapies to carry forward into phase 3 trials.
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?